Cargando…

Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease

Chronic kidney diseaQueryse (CKD) is associated with oxidative stress which can interrupt the nitric oxide (NO)/soluble guanylyl cyclase (sGC) signaling and decrease cyclic guanosine monophosphate (cGMP) production. Low cGMP concentrations can cause kidney damage and progression of CKD. The novel sG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bénardeau, Agnès, Kahnert, Antje, Schomber, Tibor, Meyer, Jutta, Pavkovic, Mira, Kretschmer, Axel, Lawrenz, Bettina, Hartmann, Elke, Mathar, Ilka, Hueser, Joerg, Kraehling, Jan R., Eitner, Frank, Hahn, Michael G., Stasch, Johannes-Peter, Sandner, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592982/ https://www.ncbi.nlm.nih.gov/pubmed/34550407 http://dx.doi.org/10.1007/s00210-021-02149-4

Ejemplares similares

The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats
por: Kraehling, Jan R., et al.
Publicado: (2023)

Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution
por: Balzer, Michael S., et al.
Publicado: (2023)

The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective
por: Krishnan, Shalini M., et al.
Publicado: (2018)

Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats
por: Hoffmann, Linda S., et al.
Publicado: (2015)

Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
por: Stehle, Daniel, et al.
Publicado: (2021)

Chronic activation of heme free soluble guanylate cyclase leads to cardio-renal protection in experimental hypertension
por: Hoffmann, Linda S, et al.
Publicado: (2013)

Soluble Guanylate Cyclase Stimulation Prevents Fibrotic Tissue Remodeling and Improves Survival in Salt-Sensitive Dahl Rats
por: Geschka, Sandra, et al.
Publicado: (2011)

Soluble Guanylate Cyclase Stimulator Vericiguat Enhances Long-Term Memory in Rats without Altering Cerebral Blood Volume
por: Nelissen, Ellis, et al.
Publicado: (2021)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

The Soluble Guanylate Cyclase Activator BAY 58-2667 Protects against Morbidity and Mortality in Endotoxic Shock by Recoupling Organ Systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems
por: Vandendriessche, Benjamin, et al.
Publicado: (2013)

Fluorescence Dequenching Makes Haem-Free Soluble Guanylate Cyclase Detectable in Living Cells
por: Hoffmann, Linda S., et al.
Publicado: (2011)

Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice
por: Thoonen, Robrecht, et al.
Publicado: (2015)

The uremic retention solute p-cresyl sulfate alters NO signal transduction by alteration of the soluble guanylate cyclase redox state
por: Meijers, Björn KI, et al.
Publicado: (2009)

Ameliorating diabetes-associated atherosclerosis and diabetic nephropathy through modulation of soluble guanylate cyclase
por: Sharma, Arpeeta, et al.
Publicado: (2023)

Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis
por: Evgenov, Oleg V, et al.
Publicado: (2011)

Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade
por: Ott, Ina M., et al.
Publicado: (2012)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

Structural studies of soluble guanylate cyclase
por: Macdonald, Jane, et al.
Publicado: (2009)

Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass
por: Radovits, Tamás, et al.
Publicado: (2009)

The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms
por: Nelissen, Ellis, et al.
Publicado: (2022)

Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease
por: Cortese-Krott, Miriam M., et al.
Publicado: (2017)

Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteosomal degradation
por: Meurer, Sabine, et al.
Publicado: (2009)

Activation of heme-free soluble guanylate cyclase with cinaciguat has beneficial cardiorenal actions when added to furosemide in experimental heart failure
por: Boerrigter, Guido, et al.
Publicado: (2011)

Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension
por: Mittendorf, Joachim, et al.
Publicado: (2009)

Soluble Guanylate Cyclase Stimulators in Heart Failure
por: Kansakar, Sajog, et al.
Publicado: (2021)

Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium
por: Chaykovska, Lyubov, et al.
Publicado: (2018)

The discovery and characterization of novel soluble guanylate cyclase stimulators
por: Masferrer, Jaime L
Publicado: (2015)

Retrospection on the Role of Soluble Guanylate Cyclase in Parkinson's Disease
por: Ghanta, Mohankrishna, et al.
Publicado: (2017)

Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation
por: Wittenborn, Elizabeth C., et al.
Publicado: (2021)

Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure
por: Mitrovic, Veselin, et al.
Publicado: (2009)

Nucleotidyl cyclase activity of recombinant soluble guanylyl cyclase
por: Rauch, Kerstin, et al.
Publicado: (2009)

The crystal structure of the catalytic domain of a eukaryotic guanylate cyclase
por: Winger, Jonathan A, et al.
Publicado: (2008)

Phosphorylation of membrane-bound guanylate cyclase of sea urchin spermatozoa
Publicado: (1986)

Vasoprotection by heme oxygenase-1: interactions with soluble guanylate cyclase
por: Durante, William
Publicado: (2011)

Crystal Structures of the Catalytic Domain of Human Soluble Guanylate Cyclase
por: Allerston, Charles K., et al.
Publicado: (2013)

Effect of Guanylate Cyclase-C Activity on Energy and Glucose Homeostasis
por: Begg, Denovan P., et al.
Publicado: (2014)

Zebrafish Guanylate Cyclase Type 3 Signaling in Cone Photoreceptors
por: Fries, Ramona, et al.
Publicado: (2013)

A new small molecule inhibitor of soluble guanylate cyclase
por: Mota, Filipa, et al.
Publicado: (2015)

Structural Insights for Activation of Retinal Guanylate Cyclase by GCAP1
por: Lim, Sunghyuk, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tuuuionq9hreu3484vfaqrcna0